Elmind Capital, LP — 13F Holdings & Portfolio

CIK 2052213 · latest 13F-HR filed 2026-08-14

Elmind Capital, LP manages $398.0M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are COGT (11.38%), SNDX (10.19%), CLDX (9.25%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 5; 16 existing positions rose in reported value and 10 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$398.0M

Long-equity book

Holdings
35

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+6 / −5 / ↑16 / ↓10

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 66.6%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Sep 3, 2026.

Assets Under Management
$613.6M
Discretionary
$613.6M
Employees
2
Accounts
3
Name Title / Status Ownership Type
ELMIND CAPITAL GP, LLC ControlGENERAL PARTNER
since Sep 2024
Less than 5%Domestic Entity
Sun, Lihan ControlCHIEF INVESTMENT OFFICER AND LIMITED PARTNER
since Sep 2024
75% or moreIndividual
Verrico, Ernest, Joseph ControlCHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER
since Oct 2024
Less than 5%Individual
Sun, Lihan Control
Indirect owner via ELMIND CAPITAL GP, LLC
MANAGING MEMBER
since Sep 2024
75% or moreIndividual
Ownership & leadership changes · 1 filing with changes since Nov 8, 2024

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 27, 2026 filing
  • ChangedELMIND CAPITAL GP, LLC · ownership 75% or more → Less than 5%
  • ChangedSun, Lihan · title FOUNDER, CHIEF INVESTMENT OFFICER AND LIMITED PARTNER → CHIEF INVESTMENT OFFICER AND LIMITED PARTNER; ownership Less than 5% → 75% or more
Nov 8, 2024 filing (earliest on record)
  • ListedELMIND CAPITAL GP, LLC · GENERAL PARTNER · 75% or more · control person
  • ListedSun, Lihan · FOUNDER, CHIEF INVESTMENT OFFICER AND LIMITED PARTNER · Less than 5% · control person
  • ListedSun, Lihan · MANAGING MEMBER · 75% or more · indirect via ELMIND CAPITAL GP, LLC · control person
  • ListedVerrico, Ernest, Joseph · CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Elmind Capital, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 COGENT BIOSCIENCES INC COGT 19240Q201 $45.3M 11.38% 1,170,740 SH
2 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $40.6M 10.19% 1,855,000 SH
3 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $36.8M 9.25% 990,000 SH
4 RELAY THERAPEUTICS INC RLAY 75943R102 $27.4M 6.89% 1,465,279 SH
5 VAXCYTE INC PCVX 92243G108 $26.3M 6.61% 452,340 SH
6 VERA THERAPEUTICS INC VERA 92337R101 $18.7M 4.71% 436,518 SH
7 PHARVARIS N V PHVS N69605108 $18.2M 4.57% 525,750 SH
8 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $18.1M 4.55% 984,931 SH
9 CYTOMX THERAPEUTICS INC. CTMX 23284F105 $17.1M 4.29% 4,550,000 SH
10 TRAVERE THERAPEUTICS INC TVTX 89422G107 $16.6M 4.18% 292,600 SH
11 LEGEND BIOTECH CORP LEGN 52490G102 $16.5M 4.14% 570,569 SH
12 BEAM THERAPEUTICS INC BEAM 07373V105 $16.3M 4.11% 476,338 SH
13 CULLINAN THERAPEUTICS INC CGEM 230031106 $12.6M 3.16% 690,000 SH
14 NURIX THERAPEUTICS INC NRIX 67080M103 $11.2M 2.80% 460,000 SH
15 KRYSTAL BIOTECH INC KRYS 501147102 $8.2M 2.05% 22,000 SH
16 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $8.1M 2.04% 15,000 SH
17 SUMMIT THERAPEUTICS INC SMMT 86627T108 $7.2M 1.81% 493,820 SH
18 INSMED INC INSM 457669307 $6.9M 1.74% 65,000 SH
19 BIOCRYST PHARMACEUTICALS INC BCRX 09058V103 $5.2M 1.31% 520,000 SH
20 MBX BIOSCIENCES INC MBX 55287L101 $5.0M 1.26% 91,000 SH
21 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $4.7M 1.17% 38,000 SH
22 UROGEN PHARMA LTD URGN M96088105 $4.4M 1.11% 120,000 SH
23 DBV TECHNOLOGIES S A DBVT 23306J309 $4.3M 1.09% 265,000 SH
24 ALUMIS INC ALMS 022307102 $3.7M 0.92% 130,000 SH
25 SUPERNUS PHARMACEUTICALS SUPN 868459108 $3.3M 0.82% 70,000 SH
26 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $2.7M 0.68% 47,000 SH
27 IMMUNOCORE HLDGS PLC IMCR 45258D105 $2.6M 0.65% 81,143 SH
28 AMYLYX PHARMACEUTICALS INC AMLX 03237H101 $2.0M 0.51% 112,000 SH
29 ALECTOR INC ALEC 014442107 $1.8M 0.45% 900,000 SH
30 SEPTERNA INC SEPN 81734D104 $1.7M 0.42% 49,444 SH
31 DESIGN THERAPEUTICS INC DSGN 25056L103 $1.6M 0.39% 107,900 SH
32 SUTRO BIOPHARMA INC STRO 869367201 $1.1M 0.27% 32,037 SH
33 WAVE LIFE SCIENCES LTD WVE Y95308105 $1.0M 0.26% 177,846 SH
34 TYRA BIOSCIENCES INC TYRA 90240B106 $638.8K 0.16% 20,000 SH
35 ENGENE THERAPEUTICS INC ENGN 29286X101 $363.3K 0.09% 210,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $398.0M 35 0001013594-26-000910
2026-03-31 2026-05-15 $352.2M 34 0001013594-26-000602
2025-12-31 2026-02-17 $338.9M 34 0001013594-26-000245
Filer Information
Address
53 WEST 53RD STREET
APARTMENT 22A
NEW YORK, NY 10019
Phone
(650) 796-6466
Filing Manager
Elmind Capital, LP
NEW YORK, NY
Signatory
Ernest Verrico
COO/CFO/CCO